Stereotaxis opened lower at $0.88, compared with its previous close of $0.90. In the last trading session, the stock traded between $0.84 and $0.90. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Stereotaxis is now worth
$ 12.58
Resulting in a loss of
$ 87.42 (87.42%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.05 (-5.78%)
Day High
$0.90
Day Low
$0.84
Day Open
$0.88
Prev Close
$0.90
Volume
14,33,400
1W Return
-10.64%
1M Return
-25.94%
3M Return
-42.12%
6M Return
-54.89%
1Y Return
-70.25%
Market Cap ($ Mn)
85
PE Ratio
-
PB Ratio
11.60
PEG Ratio
-
ROE
-358.77%
ROCE
-90.52%
EPS (TTM)
$-0.05
1 Week
-10.64%
1 Month
-25.94%
3 Months
-42.12%
6 Months
-54.89%
9 Months
-58.23%
TD Cowen maintains Buy on Stereotaxis, cuts price target to $2
TD Cowen analyst Joshua Jennings lowered Stereotaxis' price target from $3 to $2. The firm maintained a Buy rating on the company despite the target cut. No operational changes or specific financial results were cited in the brief update.
YesterdayStereotaxis Q3FY26 Results: Revenue rises 20% YoY, net loss stable at $6.5 million
Revenue rose 20% YoY to $8.9 million, driven by a 60% increase in system sales. Net loss remained flat at $6.5 million compared to the prior year quarter. Secured up to $24 million in convertible note financing to bridge to profitability. Recurring revenue grew 6% YoY but faced sequential decline due to catheter supply constraints.
2 days agoStereotaxis to report Q3FY26 financial results on November 10
Stereotaxis Inc. will report Q3FY26 results on November 10, 2026. Conference call scheduled for 4:30 pm ET following market close. Replay available for one month after the event. Company specializes in surgical robotics for endovascular intervention.
23 days agoStereotaxis to showcase AI, robotics capabilities at HRX 2026
Stereotaxis will feature Synchrony and SynX platforms at HRX 2026 in Atlanta. CEO David Fischel joins panel on autonomous EP systems on Sept 19. Synchrony received FDA clearance earlier this year and is in use globally. Company treats over 150,000 patients with its robotic systems.
1mo agoTD Cowen maintains Buy on Stereotaxis, cuts price target from $5 to $3
TD Cowen analyst Joshua Jennings maintained a Buy rating on Stereotaxis while lowering the price target from $5 to $3. The revision marks a reduction in the stated price target even as the positive Buy rating on the stock was retained.
3mo agoStereotaxis robotic catheter sales surge 270% in Q2 despite revenue miss
Stereotaxis reported Q2 revenue of $7.670 million, missing estimates by 8.14%, but achieved a 270% sequential surge in robotic catheter sales. The company completed the Robocath acquisition, secured its first US GenesisX order, and projects cash flow profitability in the first half of 2027.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Stereotaxis is now worth
$ 12.58
Resulting in a loss of
$ 87.42 (87.42%)
Note: Past profits do not guarantee future returns.
